Clinical trials: PET Positive
Neuroendocrine Carcinoma
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
To evaluate the concordance and discordance between results of 68Ga-DOTATATE PET-CT scan and OctreoScan ® which is considered standard of care diagnostic test for neuroendocrine cancers and other imaging modalities like CT…
- Trial name
- NCT01879657
- Testing
- 68Ga-DOTATATE, PET/CT, 111In-pentetreotide OctreoScan
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Radio Isotope Therapy of America
HER2-Positive Cancer
68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients
The prevalence of HER2 alterations in pan-cancer indicates a broader range of application of HER2-targeted therapies. immunohistochemistry (IHC) or amplification by fluorescence in situ hybridization (FISH) is currently the most…
- Trial name
- NCT05535621
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Prostate Carcinoma
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
This phase II trial studies how well 18F-DCFPyL positron emission tomography (PET)/magnetic resonance imaging (MRI) works for the diagnosis of prostate cancer in men with a PSA greater than or equal to 2 ng/mL.
- Trial name
- NCT04910425
- Testing
- Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Sponsor
- Northwestern University
Multiple Myeloma, Plasma Cell Myeloma
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma.
- Trial name
- NCT05892393
- Testing
- Zirconium Zr 89-DFO-YS5, Positron Emission Tomography / Computed Tomography (PET/CT), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Robert Flavell, MD, PhD
HER2 Positive or Suspicious Positive Tumors
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC
- Trial name
- NCT06548529
- Testing
- HER2 expression of PET imaging
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Stage III Breast Cancer
[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer
This study aims to evaluate the detection rate of distant metastases using [18F]FES PET/CT in patients with low-grade, ER-positive stage III breast cancer.
- Trial name
- NCT07314073
- Testing
- Fluoroestradiol (18F)
- Where
- South Korea
- Volunteers
- 85 people
- Sponsor
- Asan Medical Center
Neuroendocrine Tumors
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
68Ga-DOTANOC and 18F-FDG PET/CT have important values in the staging and clinical treatment of neuroendocrine tumors. Retrospective studies suggest that the positivite rates and SUVmax of dual imaging associated with pathological…
- Trial name
- NCT03288597
- Testing
- 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET, 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Peking University
Schizophrenia
An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia
The purpose of this study is to assess the safety, effectiveness, and plasma concentration of paliperidone (an antipsychotic medication) given once daily in the treatment of patients with schizophrenia
- Trial name
- NCT00257023
- Testing
- paliperidone
- Volunteers
- 52 people
- Sponsor
- Janssen Pharmaceutical K.K.
Metastatic Breast Cancer
Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer
Effects of fulvestrant on the ERs may be evaluable by molecular imaging using positron emission tomography with the ER-specific FES tracer.
- Trial name
- NCT03507088
- Testing
- Fluoroestradiol (18F)
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Zhimin Shao
Neuroendocrine Tumors
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
A [68]Ga-HA-DOTATATE PET/CT or PET/MRI scan is a nuclear medicine test used to create pictures of the whole body that will show where somatostatin receptors are found, including on tumours.
- Trial name
- NCT03145857
- Testing
- [68]Ga-HA-DOTATATE
- Where
- Canada
- Volunteers
- 634 people
- Sponsor
- AHS Cancer Control Alberta
Heart Failure, Obstructive Sleep Apnea
ASV Effects on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea.
Obstructive sleep apnea (OSA), central sleep apnea (CSA) and heart failure (HF) are states of metabolic demand and sympathetic nervous system (SNS) activation.
- Conditions
- Heart Failure, Obstructive Sleep Apnea, Central Sleep Apnea
- Trial name
- AMEND (NCT02116140)
- Testing
- [C11]Acetate and HED PET
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Ottawa Heart Institute Research Corporation
PSMA Positive Tumors or Tumor Tissues, Prostate Cancer Metastatic
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies.
- Trial name
- PELICAN (NCT07089550)
- Testing
- PSMA PET/CT scan
- Where
- 4 sites in Italy
- Volunteers
- 1,300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Estrogen Receptor Positive Breast Cancer, Breast Neoplasm
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
In this study, positron emission tomography (PET/CT) imaging will be used to evaluate estrogen receptor (ER) activity in sites of metastatic disease using the investigational radiotracer [18F]fluoroestradiol (FES).
- Conditions
- Estrogen Receptor Positive Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer
- Trial name
- NCT02409316
- Testing
- [18F]FES
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Pennsylvania
Hot Flashes, Breast Cancer
Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation…
- Conditions
- Hot Flashes, Breast Cancer, Acupuncture
- Trial name
- NCT05613504
- Testing
- Acupuncture treatment
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanjing University of Traditional Chinese Medicine
HODGKIN LYMPHOMA
Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)
The purpose of this multicenter clinical trial is to assess the clinical impact of dose intensification performed very early during treatment in a subset of poor prognosis, advanced-stage Hodgkin Lymphoma patients, defined as…
- Trial name
- HD0607 (NCT00795613)
- Testing
- ESCALATED BEACOPP, CONVENTIONAL ABVD
- Where
- 24 sites in Israel, Italy
- Volunteers
- 450 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Adult Medulloblastoma, Childhood Medulloblastoma
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with…
- Conditions
- Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor
- Trial name
- NCT01869725
- Testing
- gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Sue O'Dorisio
ER+ Breast Cancer
4FMFES-PET Imaging of ER+ Advanced Breast Cancers
Estrogen Receptor (ER) is a crucial prognostic factor and treatment target in breast cancer patients. Knowledge of its status greatly influences the choice of the optimal course of treatment.
- Trial name
- NCT04824014
- Testing
- 4FMFES-PET
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Esophageal Neoplasms, Gastric Neoplasms Malignant
[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors
The goal of this phase II clinical trial is to improve the selection of patients with solid tumors who would benefit from effective treatment with HER2 targeted drugs.
- Conditions
- Esophageal Neoplasms, Gastric Neoplasms Malignant, Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT05619016
- Testing
- [68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2 expression
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- Karolinska University Hospital
Metastatic Breast Cancer
Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
This is a multi-center study in France to evaluate the impact of ESTROTEP PET/CT results on the therapeutic management of patients with metastatic breast cancer (MBC).
- Trial name
- ESTROTIMP (NCT05486182)
- Testing
- 18F Fluoroestradiol Radiopharmaceutical with PET/CT
- Where
- 11 sites in France
- Volunteers
- 153 people
- Sponsor
- GE Healthcare